|Questions About Natural Products|
Co Q10 For Blood Group A
Hello, I would like to know if it can be helpful to take Enzyme Q10 with bloodgroup A.... I understand if this question cannot be answered but it would very helpful for my husband. Thanks a lot, your book is really outstanding and magnificent!!!!
The U.S. Food and Drug Administration registery of adverse effects lists Co Enzyme Q10 as a potential cause of adverse effects in 2 case reports out of approximately 3400 total reports. However, the products contained many more ingredients that CoQ10 and because of the raw material cost (Co Q10 is very expensive) one could hypothesize that the reported adverse reactions were to other components in the formulas.
The results of studies have shown that the use of coenzyme Q-10 supplements appears to be effective in the treatment of cardiovascular diseases such as congestive heart failure, cardiac arrhythmias, and hypertension. The safety of CoQ has been established in studies, and no major side effects have been associated with CoQ use. Based on its safety and apparent efficacy, the use of coenzyme Q-10, in combination with conventional medications, can be recommended for the treatment of cardiovascular disease.
In a different multicenter study, by Lampertico and Comis, the efficacy and safety of coenzyme Q-10 as supplementary therapy in patients with heart failure was examined. The study took place in Italy, with 378 physicians participating in the trial. Of those 378 physicians, 201 were cardiologists and 165 were interns. Physicians were asked to choose no more than five of their patients suffering heart failure who had been stabilized on cardiovascular therapy for at least three months to participate in the study. In all, 1715 patients were chosen, with 804 being male and 911 female. Coenzyme Q-10 was added to the traditional cardiovascular therapy at a dose of 50 mg per day in 1423 patients, while 192 patients received CoQ as their only therapy. Treatment was given over a four week period. In addition to reporting basic patient data, physicians were asked to evaluate a series of subjective and objective symptoms before treatment began, after 15 days, and after 30 days of therapy. Emphasis was placed on adverse events, and the physician was additionally asked to give their opinion on the efficacy of the therapy. The results of the trial showed a statistically significant subjective and objective improvement in the 1423 patients who received CoQ in addition to their conventional medication. Analysis showed an overall reduction in the intensity of symptoms after two and four weeks of treatment (p<0.01), and statistically significant differences in systolic and dyastolic blood pressure and heart rate were found (p<0.01). Also of note, the incidence of clinical improvement in the group of patients which received only coenzyme Q-10 was the same as the group receiving CoQ in addition to their conventional medication. Incidence of adverse effects decreased from 2.2% after two weeks, to 0.4% at the end of four weeks. Physicians' opinion of treatment efficacy was rated as excellent to good for 71.1% of the patients. A limitation of the study is its focus on people of Italian ethnicity. (1)
Since blood group A is a recognized risk factor for cardiovascular disease (2), it would appear that taking supplemental CoQ10 would be rational. A typical dose can range from 30-100mg daily, although I tend to recommend the lower doses more frequently. Other blood groups may benefit from Co Q10 supplementation as well, although I tend to use it more frequently in group A patients.
One caveat to remember is that without a small amount of lipid (fat) in the gut the absorption of CoQ10 is virtually nil. Thus to insure proper assimilation, CoQ10 should be taken with the largest meal of the day.
1. Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clin Investig 1993; 71:S129-S133.
2. Suadicani P, Hein HO, Gyntelberg F.Socioeconomic status, ABO phenotypes and risk of ischaemic heart disease: an 8-year follow-up in the Copenhagen Male Study. J Cardiovasc Risk. 2000 Aug;7(4):277-83.